Drug Sponsors

Incyte to establish European headquarters in Geneva

Wednesday, April 15, 2015

Incyte, a Wilmington, Del.-based biopharmaceutical company, will establish the new headquarters of Incyte Europe in Geneva, Switzerland. Incyte intends to use Incyte Europe as the base from which it will conduct its European clinical development operations, and expects to occupy the 9,000-square-foot facility by mid-2015.

[Read More]

Mylan notifies Perrigo of HSR filing regarding proposed acquisition

Monday, April 13, 2015

Mylan, a global generics and specialty pharmaceutical company, has provided Perrigo, an Irish international manufacturer of over-the-counter pharmaceuticals, with notice of its filing of the pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its proposed acquisition of Perrigo, as required by the HSR Act. Mylan proposed to acquire Perrigo for $205 per share in a cash-and-stock transaction on April 6.

[Read More]

Biotech companies raise record amount of capital in Q1

Monday, April 13, 2015

Although the financial market turbu­lence in the first quarter of 2015 scared some investors, it did not slow down public and private biotechnology companies from collectively raising a record-setting $14 billion—nearly 50% more than the total raised in the first quarter of 2014, which was consid­ered the high watermark for the industry.

[Read More]

Pfizer launches competitive grants program for cardiovascular disease research

Friday, April 10, 2015

Pfizer has launched a new competitive grants program to support research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease. This competitive grants program, which is an extension of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Cardiovascular program, is part of Pfizer’s ongoing commitment to translate scientific discoveries into innovative medicines for patients with cardiovascular disease.

[Read More]

Eisai to restructure U.S. operations, cut workforce 25%

Friday, April 10, 2015

Eisai Inc., a U.S. subsidiary of Eisai Co., a global R&D-based pharmaceutical company headquartered in Japan, plans to restructure its operations in the U.S., including a reduction of its workforce by approximately 25% across various U.S. functions. This realignment supports Eisai’s desire to create a more efficient and focused organization.

[Read More]